Drug project high-priority medications: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
Line 16: Line 16:


====List of high-priority medications====
====List of high-priority medications====
{| class="wikitable"
{| class="wikitable"
| align="center" style="background:#f0f0f0;"|'''Year'''
| align="center" style="background:#f0f0f0;"|'''Year'''
Line 25: Line 26:
| align="center" style="background:#f0f0f0;"|'''Approval Date'''
| align="center" style="background:#f0f0f0;"|'''Approval Date'''
|-
|-
| 2019||12||Polivy||Polatuzumab vedotin-piiq||[[Polatuzumab vedotin-piiq]]||Polatuzumab vedotin-piiq||6/10/2019
| 2019||12||Polivy||Polatuzumab vedotin-piiq||[[Polatuzumab vedotin-piiq]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Polivy Polivy]||6/10/2019
|-
|-
| 2019||11||Piqray||Alpelisib||[[Alpelisib]]||Alpelisib||5/24/2019
| 2019||11||Piqray||Alpelisib||[[Alpelisib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Piqray Piqray]||5/24/2019
|-
|-
| 2019||10||Vyndaqel||Tafamidis meglumine||[[Tafamidis meglumine]]||Tafamidis meglumine||5/3/2019
| 2019||10||Vyndaqel||Tafamidis meglumine||[[Tafamidis meglumine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vyndaqel Vyndaqel]||5/3/2019
|-
|-
| 2019||9||Skyrizi||Risankizumab-rzaa||[[Risankizumab-rzaa]]||Risankizumab-rzaa||4/23/2019
| 2019||9||Skyrizi||Risankizumab-rzaa||[[Risankizumab-rzaa]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Skyrizi Skyrizi]||4/23/2019
|-
|-
| 2019||8||Balversa||Erdafitinib||[[Erdafitinib]]||Erdafitinib||4/12/2019
| 2019||8||Balversa||Erdafitinib||[[Erdafitinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Balversa Balversa]||4/12/2019
|-
|-
| 2019||7||Evenity||Romosozumab-aqqg||[[Romosozumab-aqqg]]||Romosozumab-aqqg||4/9/2019
| 2019||7||Evenity||Romosozumab-aqqg||[[Romosozumab-aqqg]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Evenity Evenity]||4/9/2019
|-
|-
| 2019||6||Mayzent||Siponimod||[[Siponimod]]||Siponimod||3/26/2019
| 2019||6||Mayzent||Siponimod||[[Siponimod]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mayzent Mayzent]||3/26/2019
|-
|-
| 2019||5||Sunosi||Solriamfetol||[[Solriamfetol]]||Solriamfetol||3/20/2019
| 2019||5||Sunosi||Solriamfetol||[[Solriamfetol]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sunosi Sunosi]||3/20/2019
|-
|-
| 2019||4||Zulresso||Brexanolone||[[Brexanolone]]||Brexanolone||3/19/2019
| 2019||4||Zulresso||Brexanolone||[[Brexanolone]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Zulresso Zulresso]||3/19/2019
|-
|-
| 2019||3||Egaten||Triclabendazole||[[Triclabendazole]]||Triclabendazole||2/13/2019
| 2019||3||Egaten||Triclabendazole||[[Triclabendazole]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Egaten Egaten]||2/13/2019
|-
|-
| 2019||2||Cablivi||Caplacizumab-yhdp||[[Caplacizumab-yhdp]]||Caplacizumab-yhdp||2/6/2019
| 2019||2||Cablivi||Caplacizumab-yhdp||[[Caplacizumab-yhdp]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cablivi Cablivi]||2/6/2019
|-
|-
| 2019||1||Jeuveau||Prabotulinumtoxina-xvfs||[[Prabotulinumtoxina-xvfs]]||Prabotulinumtoxina-xvfs||2/1/2019
| 2019||1||Jeuveau||Prabotulinumtoxina-xvfs||[[Prabotulinumtoxina-xvfs]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Jeuveau Jeuveau]||2/1/2019
|-
|-
| 2018||59||Ultomiris||Ravulizumab||[[Ravulizumab]]||Ravulizumab||12/21/2018
| 2018||59||Ultomiris||Ravulizumab||[[Ravulizumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ultomiris Ultomiris]||12/21/2018
|-
|-
| 2018||58||Elzonris||Tagraxofusp-erzs||[[Tagraxofusp-erzs]]||Tagraxofusp-erzs||12/21/2018
| 2018||58||Elzonris||Tagraxofusp-erzs||[[Tagraxofusp-erzs]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Elzonris Elzonris]||12/21/2018
|-
|-
| 2018||57||Asparlas||Calaspargase pegol-mknl||[[Calaspargase pegol-mknl]]||Calaspargase pegol-mknl||12/20/2018
| 2018||57||Asparlas||Calaspargase pegol-mknl||[[Calaspargase pegol-mknl]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Asparlas Asparlas]||12/20/2018
|-
|-
| 2018||56||Motegrity||Prucalopride||[[Prucalopride]]||Prucalopride||12/14/2018
| 2018||56||Motegrity||Prucalopride||[[Prucalopride]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Motegrity Motegrity]||12/14/2018
|-
|-
| 2018||55||Xospata||Gilteritinib||[[Gilteritinib]]||Gilteritinib||11/28/2018
| 2018||55||Xospata||Gilteritinib||[[Gilteritinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xospata Xospata]||11/28/2018
|-
|-
| 2018||54||Firdapse||Amifampridine||[[Amifampridine]]||Amifampridine||11/28/2028
| 2018||54||Firdapse||Amifampridine||[[Amifampridine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Firdapse Firdapse]||11/28/2028
|-
|-
| 2018||53||Vitrakvi||Larotrectinib||[[Larotrectinib]]||Larotrectinib||11/26/2018
| 2018||53||Vitrakvi||Larotrectinib||[[Larotrectinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vitrakvi Vitrakvi]||11/26/2018
|-
|-
| 2018||52||Daurismo||Glasdegib||[[Glasdegib]]||Glasdegib||11/21/2018
| 2018||52||Daurismo||Glasdegib||[[Glasdegib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Daurismo Daurismo]||11/21/2018
|-
|-
| 2018||51||Gamifant||Emapalumab-lzsgemapalumab-lzsg||[[Emapalumab-lzsgemapalumab-lzsg]]||Emapalumab-lzsgemapalumab-lzsg||11/20/2018
| 2018||51||Gamifant||Emapalumab-lzsgemapalumab-lzsg||[[Emapalumab-lzsgemapalumab-lzsg]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Gamifant Gamifant]||11/20/2018
|-
|-
| 2018||50||Aemcolo||Rifamycin||[[Rifamycin]]||Rifamycin||11/16/2018
| 2018||50||Aemcolo||Rifamycin||[[Rifamycin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Aemcolo Aemcolo]||11/16/2018
|-
|-
| 2018||49||Yupelri||Revefenacin||[[Revefenacin]]||Revefenacin||11/9/2018
| 2018||49||Yupelri||Revefenacin||[[Revefenacin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Yupelri Yupelri]||11/9/2018
|-
|-
| 2018||48||Lorbrena||Lorlatinib||[[Lorlatinib]]||Lorlatinib||11/2/2018
| 2018||48||Lorbrena||Lorlatinib||[[Lorlatinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lorbrena Lorbrena]||11/2/2018
|-
|-
| 2018||47||Xofluza||Baloxavir marboxil||[[Baloxavir marboxil]]||Baloxavir marboxil||10/24/2018
| 2018||47||Xofluza||Baloxavir marboxil||[[Baloxavir marboxil]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xofluza Xofluza]||10/24/2018
|-
|-
| 2018||46||Talzenna||Talazoparib||[[Talazoparib]]||Talazoparib||10/16/2018
| 2018||46||Talzenna||Talazoparib||[[Talazoparib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Talzenna Talzenna]||10/16/2018
|-
|-
| 2018||45||Tegsedi||Inotersen||[[Inotersen]]||Inotersen||10/5/2018
| 2018||45||Tegsedi||Inotersen||[[Inotersen]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tegsedi Tegsedi]||10/5/2018
|-
|-
| 2018||44||Revcovi||Elapegademase-lvlr||[[Elapegademase-lvlr]]||Elapegademase-lvlr||10/5/2018
| 2018||44||Revcovi||Elapegademase-lvlr||[[Elapegademase-lvlr]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Revcovi Revcovi]||10/5/2018
|-
|-
| 2018||43||Nuzyra||Omadacycline||[[Omadacycline]]||Omadacycline||10/2/2018
| 2018||43||Nuzyra||Omadacycline||[[Omadacycline]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Nuzyra Nuzyra]||10/2/2018
|-
|-
| 2018||42||Seysara||Sarecycline||[[Sarecycline]]||Sarecycline||10/1/2018
| 2018||42||Seysara||Sarecycline||[[Sarecycline]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Seysara Seysara]||10/1/2018
|-
|-
| 2018||41||Libtayo||Cemiplimab-rwlc||[[Cemiplimab-rwlc]]||Cemiplimab-rwlc||9/28/2018
| 2018||41||Libtayo||Cemiplimab-rwlc||[[Cemiplimab-rwlc]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Libtayo Libtayo]||9/28/2018
|-
|-
| 2018||40||Vizimpro||Dacomitinib||[[Dacomitinib]]||Dacomitinib||9/27/2018
| 2018||40||Vizimpro||Dacomitinib||[[Dacomitinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vizimpro Vizimpro]||9/27/2018
|-
|-
| 2018||39||Emgality||Galcanezumab-gnlm||[[Galcanezumab-gnlm]]||Galcanezumab-gnlm||9/27/2018
| 2018||39||Emgality||Galcanezumab-gnlm||[[Galcanezumab-gnlm]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Emgality Emgality]||9/27/2018
|-
|-
| 2018||38||Copiktra||Duvelisib||[[Duvelisib]]||Duvelisib||9/24/2018
| 2018||38||Copiktra||Duvelisib||[[Duvelisib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Copiktra Copiktra]||9/24/2018
|-
|-
| 2018||37||Ajovy||Fremanezumab-vfrm||[[Fremanezumab-vfrm]]||Fremanezumab-vfrm||9/14/2018
| 2018||37||Ajovy||Fremanezumab-vfrm||[[Fremanezumab-vfrm]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ajovy Ajovy]||9/14/2018
|-
|-
| 2018||36||Lumoxiti||Moxetumomab pasudotox-tdfk||[[Moxetumomab pasudotox-tdfk]]||Moxetumomab pasudotox-tdfk||9/13/2018
| 2018||36||Lumoxiti||Moxetumomab pasudotox-tdfk||[[Moxetumomab pasudotox-tdfk]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lumoxiti Lumoxiti]||9/13/2018
|-
|-
| 2018||35||Pifeltro||Doravirine||[[Doravirine]]||Doravirine||8/30/2018
| 2018||35||Pifeltro||Doravirine||[[Doravirine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pifeltro Pifeltro]||8/30/2018
|-
|-
| 2018||34||Xerava||Eravacycline||[[Eravacycline]]||Eravacycline||8/27/2018
| 2018||34||Xerava||Eravacycline||[[Eravacycline]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xerava Xerava]||8/27/2018
|-
|-
| 2018||33||Takhzyro||Lanadelumab||[[Lanadelumab]]||Lanadelumab||8/23/2018
| 2018||33||Takhzyro||Lanadelumab||[[Lanadelumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Takhzyro Takhzyro]||8/23/2018
|-
|-
| 2018||32||Oxervate||Cenegermin-bkbj||[[Cenegermin-bkbj]]||Cenegermin-bkbj||8/22/2018
| 2018||32||Oxervate||Cenegermin-bkbj||[[Cenegermin-bkbj]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Oxervate Oxervate]||8/22/2018
|-
|-
| 2018||31||Diacomit||Stiripentol||[[Stiripentol]]||Stiripentol||8/20/2018
| 2018||31||Diacomit||Stiripentol||[[Stiripentol]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Diacomit Diacomit]||8/20/2018
|-
|-
| 2018||30||Galafold||Migalastat||[[Migalastat]]||Migalastat||8/10/2018
| 2018||30||Galafold||Migalastat||[[Migalastat]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Galafold Galafold]||8/10/2018
|-
|-
| 2018||29||Annovera||Segesterone acetate and ethinyl estradiol vaginal system||[[Segesterone acetate and ethinyl estradiol vaginal system]]||Segesterone acetate and ethinyl estradiol vaginal system||8/10/2018
| 2018||29||Annovera||Segesterone acetate and ethinyl estradiol vaginal system||[[Segesterone acetate and ethinyl estradiol vaginal system]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Annovera Annovera]||8/10/2018
|-
|-
| 2018||28||Onpattro||Patisiran||[[Patisiran]]||Patisiran||8/10/2018
| 2018||28||Onpattro||Patisiran||[[Patisiran]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Onpattro Onpattro]||8/10/2018
|-
|-
| 2018||27||Poteligeo||Mogamulizumab-kpkc||[[Mogamulizumab-kpkc]]||Mogamulizumab-kpkc||8/8/2018
| 2018||27||Poteligeo||Mogamulizumab-kpkc||[[Mogamulizumab-kpkc]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Poteligeo Poteligeo]||8/8/2018
|-
|-
| 2018||26||Mulpleta||Lusutrombopag||[[Lusutrombopag]]||Lusutrombopag||7/31/2018
| 2018||26||Mulpleta||Lusutrombopag||[[Lusutrombopag]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mulpleta Mulpleta]||7/31/2018
|-
|-
| 2018||25||Omegaven||Fish oil triglycerides||[[Fish oil triglycerides]]||Fish oil triglycerides||7/27/2018
| 2018||25||Omegaven||Fish oil triglycerides||[[Fish oil triglycerides]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Omegaven Omegaven]||7/27/2018
|-
|-
| 2018||24||Orilissa||Elagolix sodium||[[Elagolix sodium]]||Elagolix sodium||7/23/2018
| 2018||24||Orilissa||Elagolix sodium||[[Elagolix sodium]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Orilissa Orilissa]||7/23/2018
|-
|-
| 2018||23||Krintafel||Tafenoquine||[[Tafenoquine]]||Tafenoquine||7/20/2018
| 2018||23||Krintafel||Tafenoquine||[[Tafenoquine]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Krintafel Krintafel]||7/20/2018
|-
|-
| 2018||22||Tibsovo||Ivosidenib||[[Ivosidenib]]||Ivosidenib||7/20/2018
| 2018||22||Tibsovo||Ivosidenib||[[Ivosidenib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tibsovo Tibsovo]||7/20/2018
|-
|-
| 2018||21||TPOXX||Tecovirimat||[[Tecovirimat]]||Tecovirimat||7/13/2018
| 2018||21||TPOXX||Tecovirimat||[[Tecovirimat]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TPOXX TPOXX]||7/13/2018
|-
|-
| 2018||20||Braftovi||Encorafenib||[[Encorafenib]]||Encorafenib||6/27/2018
| 2018||20||Braftovi||Encorafenib||[[Encorafenib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Braftovi Braftovi]||6/27/2018
|-
|-
| 2018||19||Mektovi||Binimetinib||[[Binimetinib]]||Binimetinib||6/27/2018
| 2018||19||Mektovi||Binimetinib||[[Binimetinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mektovi Mektovi]||6/27/2018
|-
|-
| 2018||18||Zemdri||Plazomicin||[[Plazomicin]]||Plazomicin||6/25/2018
| 2018||18||Zemdri||Plazomicin||[[Plazomicin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Zemdri Zemdri]||6/25/2018
|-
|-
| 2018||17||Epidioloex||Cannabidiol||[[Cannabidiol]]||Cannabidiol||6/25/2018
| 2018||17||Epidioloex||Cannabidiol||[[Cannabidiol]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Epidioloex Epidioloex]||6/25/2018
|-
|-
| 2018||16||Moxidectin||Moxidectin||[[Moxidectin]]||Moxidectin||6/13/2018
| 2018||16||Moxidectin||Moxidectin||[[Moxidectin]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Moxidectin Moxidectin]||6/13/2018
|-
|-
| 2018||15||Olumiant||Baricitinib||[[Baricitinib]]||Baricitinib||5/31/2018
| 2018||15||Olumiant||Baricitinib||[[Baricitinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Olumiant Olumiant]||5/31/2018
|-
|-
| 2018||14||Palynziq||Pegvaliase-pqpz||[[Pegvaliase-pqpz]]||Pegvaliase-pqpz||5/24/2018
| 2018||14||Palynziq||Pegvaliase-pqpz||[[Pegvaliase-pqpz]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Palynziq Palynziq]||5/24/2018
|-
|-
| 2018||13||Doptelet||Avatrombopag||[[Avatrombopag]]||Avatrombopag||5/21/2018
| 2018||13||Doptelet||Avatrombopag||[[Avatrombopag]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Doptelet Doptelet]||5/21/2018
|-
|-
| 2018||12||Lokelma||Sodium zirconium cyclosilicate||[[Sodium zirconium cyclosilicate]]||Sodium zirconium cyclosilicate||5/18/2018
| 2018||12||Lokelma||Sodium zirconium cyclosilicate||[[Sodium zirconium cyclosilicate]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lokelma Lokelma]||5/18/2018
|-
|-
| 2018||11||Aimovig||Erenumab-aooe||[[Erenumab-aooe]]||Erenumab-aooe||5/17/2018
| 2018||11||Aimovig||Erenumab-aooe||[[Erenumab-aooe]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Aimovig Aimovig]||5/17/2018
|-
|-
| 2018||10||Lucemyra||Lofexidine hydrochloride||[[Lofexidine hydrochloride]]||Lofexidine hydrochloride||5/16/2018
| 2018||10||Lucemyra||Lofexidine hydrochloride||[[Lofexidine hydrochloride]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lucemyra Lucemyra]||5/16/2018
|-
|-
| 2018||9||Akynzeo||Fosnetupitant and palonosetron||[[Fosnetupitant and palonosetron]]||Fosnetupitant and palonosetron||4/19/2018
| 2018||9||Akynzeo||Fosnetupitant and palonosetron||[[Fosnetupitant and palonosetron]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Akynzeo Akynzeo]||4/19/2018
|-
|-
| 2018||8||Crysvita||Burosumab-twza||[[Burosumab-twza]]||Burosumab-twza||4/17/2018
| 2018||8||Crysvita||Burosumab-twza||[[Burosumab-twza]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Crysvita Crysvita]||4/17/2018
|-
|-
| 2018||7||Tavalisse||Fostamatinib||[[Fostamatinib]]||Fostamatinib||4/17/2018
| 2018||7||Tavalisse||Fostamatinib||[[Fostamatinib]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tavalisse Tavalisse]||4/17/2018
|-
|-
| 2018||6||Ilumya||Tildrakizumab||[[Tildrakizumab]]||Tildrakizumab||3/20/2018
| 2018||6||Ilumya||Tildrakizumab||[[Tildrakizumab]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ilumya Ilumya]||3/20/2018
|-
|-
| 2018||5||Trogarzo||Ibalizumab-uiyk||[[Ibalizumab-uiyk]]||Ibalizumab-uiyk||3/6/2018
| 2018||5||Trogarzo||Ibalizumab-uiyk||[[Ibalizumab-uiyk]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trogarzo Trogarzo]||3/6/2018
|-
|-
| 2018||4||Erleada||Apalutamide||[[Apalutamide]]||Apalutamide||2/14/2018
| 2018||4||Erleada||Apalutamide||[[Apalutamide]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Erleada Erleada]||2/14/2018
|-
|-
| 2018||3||Symdeko||Tezacaftor; ivacaftor||[[Tezacaftor; ivacaftor]]||Tezacaftor; ivacaftor||2/12/2018
| 2018||3||Symdeko||Tezacaftor; ivacaftor||[[Tezacaftor; ivacaftor]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Symdeko Symdeko]||2/12/2018
|-
|-
| 2018||2||Biktarvy||Bictegravir, embitcitabine, tenofovir alafenamide||[[Bictegravir, embitcitabine, tenofovir alafenamide]]||Bictegravir, embitcitabine, tenofovir alafenamide||2/7/2018
| 2018||2||Biktarvy||Bictegravir, embitcitabine, tenofovir alafenamide||[[Bictegravir, embitcitabine, tenofovir alafenamide]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Biktarvy Biktarvy]||2/7/2018
|-
|-
| 2018||1||Lutathera||Lutetium lu 177 dotatate||[[Lutetium lu 177 dotatate]]||Lutetium lu 177 dotatate||1/26/2018
| 2018||1||Lutathera||Lutetium lu 177 dotatate||[[Lutetium lu 177 dotatate]]||[https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lutathera Lutathera]||1/26/2018
|}
|}
</div>
</div>

Revision as of 17:40, 19 June 2019

   Mission Statement   
   Tutorial   
   Editor's Checklist   

WikiDoc Drug Project — High-Priority Medications

List of high-priority medications

Year No. Brand Name Active Ingredient Page Link DailyMed Search Approval Date
2019 12 Polivy Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq Polivy 6/10/2019
2019 11 Piqray Alpelisib Alpelisib Piqray 5/24/2019
2019 10 Vyndaqel Tafamidis meglumine Tafamidis meglumine Vyndaqel 5/3/2019
2019 9 Skyrizi Risankizumab-rzaa Risankizumab-rzaa Skyrizi 4/23/2019
2019 8 Balversa Erdafitinib Erdafitinib Balversa 4/12/2019
2019 7 Evenity Romosozumab-aqqg Romosozumab-aqqg Evenity 4/9/2019
2019 6 Mayzent Siponimod Siponimod Mayzent 3/26/2019
2019 5 Sunosi Solriamfetol Solriamfetol Sunosi 3/20/2019
2019 4 Zulresso Brexanolone Brexanolone Zulresso 3/19/2019
2019 3 Egaten Triclabendazole Triclabendazole Egaten 2/13/2019
2019 2 Cablivi Caplacizumab-yhdp Caplacizumab-yhdp Cablivi 2/6/2019
2019 1 Jeuveau Prabotulinumtoxina-xvfs Prabotulinumtoxina-xvfs Jeuveau 2/1/2019
2018 59 Ultomiris Ravulizumab Ravulizumab Ultomiris 12/21/2018
2018 58 Elzonris Tagraxofusp-erzs Tagraxofusp-erzs Elzonris 12/21/2018
2018 57 Asparlas Calaspargase pegol-mknl Calaspargase pegol-mknl Asparlas 12/20/2018
2018 56 Motegrity Prucalopride Prucalopride Motegrity 12/14/2018
2018 55 Xospata Gilteritinib Gilteritinib Xospata 11/28/2018
2018 54 Firdapse Amifampridine Amifampridine Firdapse 11/28/2028
2018 53 Vitrakvi Larotrectinib Larotrectinib Vitrakvi 11/26/2018
2018 52 Daurismo Glasdegib Glasdegib Daurismo 11/21/2018
2018 51 Gamifant Emapalumab-lzsgemapalumab-lzsg Emapalumab-lzsgemapalumab-lzsg Gamifant 11/20/2018
2018 50 Aemcolo Rifamycin Rifamycin Aemcolo 11/16/2018
2018 49 Yupelri Revefenacin Revefenacin Yupelri 11/9/2018
2018 48 Lorbrena Lorlatinib Lorlatinib Lorbrena 11/2/2018
2018 47 Xofluza Baloxavir marboxil Baloxavir marboxil Xofluza 10/24/2018
2018 46 Talzenna Talazoparib Talazoparib Talzenna 10/16/2018
2018 45 Tegsedi Inotersen Inotersen Tegsedi 10/5/2018
2018 44 Revcovi Elapegademase-lvlr Elapegademase-lvlr Revcovi 10/5/2018
2018 43 Nuzyra Omadacycline Omadacycline Nuzyra 10/2/2018
2018 42 Seysara Sarecycline Sarecycline Seysara 10/1/2018
2018 41 Libtayo Cemiplimab-rwlc Cemiplimab-rwlc Libtayo 9/28/2018
2018 40 Vizimpro Dacomitinib Dacomitinib Vizimpro 9/27/2018
2018 39 Emgality Galcanezumab-gnlm Galcanezumab-gnlm Emgality 9/27/2018
2018 38 Copiktra Duvelisib Duvelisib Copiktra 9/24/2018
2018 37 Ajovy Fremanezumab-vfrm Fremanezumab-vfrm Ajovy 9/14/2018
2018 36 Lumoxiti Moxetumomab pasudotox-tdfk Moxetumomab pasudotox-tdfk Lumoxiti 9/13/2018
2018 35 Pifeltro Doravirine Doravirine Pifeltro 8/30/2018
2018 34 Xerava Eravacycline Eravacycline Xerava 8/27/2018
2018 33 Takhzyro Lanadelumab Lanadelumab Takhzyro 8/23/2018
2018 32 Oxervate Cenegermin-bkbj Cenegermin-bkbj Oxervate 8/22/2018
2018 31 Diacomit Stiripentol Stiripentol Diacomit 8/20/2018
2018 30 Galafold Migalastat Migalastat Galafold 8/10/2018
2018 29 Annovera Segesterone acetate and ethinyl estradiol vaginal system Segesterone acetate and ethinyl estradiol vaginal system Annovera 8/10/2018
2018 28 Onpattro Patisiran Patisiran Onpattro 8/10/2018
2018 27 Poteligeo Mogamulizumab-kpkc Mogamulizumab-kpkc Poteligeo 8/8/2018
2018 26 Mulpleta Lusutrombopag Lusutrombopag Mulpleta 7/31/2018
2018 25 Omegaven Fish oil triglycerides Fish oil triglycerides Omegaven 7/27/2018
2018 24 Orilissa Elagolix sodium Elagolix sodium Orilissa 7/23/2018
2018 23 Krintafel Tafenoquine Tafenoquine Krintafel 7/20/2018
2018 22 Tibsovo Ivosidenib Ivosidenib Tibsovo 7/20/2018
2018 21 TPOXX Tecovirimat Tecovirimat TPOXX 7/13/2018
2018 20 Braftovi Encorafenib Encorafenib Braftovi 6/27/2018
2018 19 Mektovi Binimetinib Binimetinib Mektovi 6/27/2018
2018 18 Zemdri Plazomicin Plazomicin Zemdri 6/25/2018
2018 17 Epidioloex Cannabidiol Cannabidiol Epidioloex 6/25/2018
2018 16 Moxidectin Moxidectin Moxidectin Moxidectin 6/13/2018
2018 15 Olumiant Baricitinib Baricitinib Olumiant 5/31/2018
2018 14 Palynziq Pegvaliase-pqpz Pegvaliase-pqpz Palynziq 5/24/2018
2018 13 Doptelet Avatrombopag Avatrombopag Doptelet 5/21/2018
2018 12 Lokelma Sodium zirconium cyclosilicate Sodium zirconium cyclosilicate Lokelma 5/18/2018
2018 11 Aimovig Erenumab-aooe Erenumab-aooe Aimovig 5/17/2018
2018 10 Lucemyra Lofexidine hydrochloride Lofexidine hydrochloride Lucemyra 5/16/2018
2018 9 Akynzeo Fosnetupitant and palonosetron Fosnetupitant and palonosetron Akynzeo 4/19/2018
2018 8 Crysvita Burosumab-twza Burosumab-twza Crysvita 4/17/2018
2018 7 Tavalisse Fostamatinib Fostamatinib Tavalisse 4/17/2018
2018 6 Ilumya Tildrakizumab Tildrakizumab Ilumya 3/20/2018
2018 5 Trogarzo Ibalizumab-uiyk Ibalizumab-uiyk Trogarzo 3/6/2018
2018 4 Erleada Apalutamide Apalutamide Erleada 2/14/2018
2018 3 Symdeko Tezacaftor; ivacaftor Tezacaftor; ivacaftor Symdeko 2/12/2018
2018 2 Biktarvy Bictegravir, embitcitabine, tenofovir alafenamide Bictegravir, embitcitabine, tenofovir alafenamide Biktarvy 2/7/2018
2018 1 Lutathera Lutetium lu 177 dotatate Lutetium lu 177 dotatate Lutathera 1/26/2018
Retrieved from "https://www.wikidoc.org/index.php?title=Drug_project_high-priority_medications&oldid=1572625"